Axsome Therapeutics Inc (NASDAQ:AXSM)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $40.25 and last traded at $39.12, with a volume of 2114 shares traded. The stock had previously closed at $39.37.
Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, October 17th. ValuEngine downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. BidaskClub upgraded shares of Axsome Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $55.00 price target (up previously from $45.00) on shares of Axsome Therapeutics in a report on Tuesday. Finally, Guggenheim initiated coverage on shares of Axsome Therapeutics in a report on Wednesday, October 16th. They issued a “buy” rating and a $48.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $37.63.
The company has a debt-to-equity ratio of 2.80, a current ratio of 2.39 and a quick ratio of 2.39. The firm has a market capitalization of $1.36 billion, a PE ratio of -39.66 and a beta of 2.84. The company has a 50-day moving average price of $27.72 and a 200-day moving average price of $25.21.
In other news, CFO Nick Pizzie bought 2,180 shares of Axsome Therapeutics stock in a transaction on Thursday, September 26th. The shares were bought at an average cost of $24.80 per share, for a total transaction of $54,064.00. Following the acquisition, the chief financial officer now owns 40,440 shares in the company, valued at $1,002,912. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.50% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of AXSM. BlackRock Inc. boosted its holdings in shares of Axsome Therapeutics by 263.1% during the second quarter. BlackRock Inc. now owns 1,690,522 shares of the company’s stock worth $43,531,000 after purchasing an additional 1,224,935 shares during the last quarter. VHCP Management III LLC grew its position in shares of Axsome Therapeutics by 50.9% in the second quarter. VHCP Management III LLC now owns 1,611,329 shares of the company’s stock valued at $41,492,000 after purchasing an additional 543,285 shares during the period. Vanguard Group Inc. grew its position in shares of Axsome Therapeutics by 27.8% in the second quarter. Vanguard Group Inc. now owns 1,152,285 shares of the company’s stock valued at $29,671,000 after purchasing an additional 250,498 shares during the period. VHCP Management II LLC increased its stake in Axsome Therapeutics by 56.1% in the second quarter. VHCP Management II LLC now owns 892,946 shares of the company’s stock valued at $22,993,000 after purchasing an additional 320,990 shares during the last quarter. Finally, State Street Corp increased its stake in Axsome Therapeutics by 12.0% in the third quarter. State Street Corp now owns 729,682 shares of the company’s stock valued at $14,769,000 after purchasing an additional 78,209 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors.
Axsome Therapeutics Company Profile (NASDAQ:AXSM)
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Recommended Story: Mutual Funds
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.